• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

Teens with Asthma Favor E-cigs, Hookah

Slideshow

Middle/high school students with asthma were found more likely to use 5 different tobacco products vs classmates without asthma.

Related Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
FDA Updates Albuterol/Budesonide Label to Include Evidence of Exacerbation Risk Reduction in Mild Asthma

FDA Updates Albuterol/Budesonide Label to Include Evidence of Exacerbation Risk Reduction in Mild Asthma

Sydney Jennings
September 18th 2025
Article

The updated prescribing information includes phase 3b BATURA trial results showing a 46% reduction in severe exacerbations in mild asthma vs albuterol.

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Sydney Jennings
May 20th 2022
Podcast

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Digital Asthma Program Improves Symptom Control in Adults: Daily Dose / image credit: ©New Africa/AdobeStock

Digital Asthma Program Improves Symptom Control in Adults: Daily Dose

Sydney Jennings
August 6th 2025
Article

Your daily dose of the clinical news you may have missed.

Site Logo

Eternal Springs

Faith T. Fitzgerald, MD
January 13th 2010
Podcast

Doctors, especially primary care doctors, love stories. We love hearing them from patients and telling them to one another. “Anecdotal learning” it’s called by some (somewhat derisively because it’s not science).

Upstream Bio's TSLP Antagonist Verekitug Enters Global Phase 2 Trial for COPD / image credit courtesy of Upstream Bio

Upstream Bio's TSLP Antagonist Verekitug Enters Global Phase 2 Trial for COPD

Grace Halsey
July 11th 2025
Article

Verekitug is the only biologic in development for COPD that targets the TSLP receptor directly.

Circulating Inflammatory Cells Persist in Severe Asthma Despite Biologic Therapy, Study Shows / image courtesy of Karolinska Institutet

Circulating Inflammatory Cells Persist in Severe Asthma Despite Biologic Therapy, Study Shows

Grace Halsey
July 2nd 2025
Article

Research from the Karolinska Institute reveals that therapies such as dupilumab and mepolizumab may not eliminate Th2 lymphocytes, raising concerns about long-term remission.

© 2025 MJH Life Sciences

All rights reserved.